...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Surgical Oncology >Is advanced hepatocellular carcinoma amenable of cure by liver transplantation with sorafenib as a neoadjuvant approach plus m-TOR inhibitors monotherapy?
【24h】

Is advanced hepatocellular carcinoma amenable of cure by liver transplantation with sorafenib as a neoadjuvant approach plus m-TOR inhibitors monotherapy?

机译：索拉非尼作为新辅助治疗方法加上m-TOR抑制剂的单药治疗是否可以通过肝移植治愈晚期肝细胞癌？

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Primary liver cancer is the fifth most common cancer worldwide and the third most common cause of death from cancer, resulting in more than 600,000 deaths per year [1]. While, on one hand we have, different therapeutic opportunities at our disposal for early stage hepatocellular carcinoma (resection, local ablation either with radio-frequency or percutaneous ethanol injection, liver transplantation), on the other hand advanced stage represents yet a challenge due to the paucity of effective treatment options. The introduction of targeted therapies represents a new era in drug development and implies the choice to attack pathways that are critical for cancer survival and progression. In particular angiogenic signalling factors, growth signalling pathways mediated through tyrosine kinase seem to have a peculiar role in the pathogenesis of hepatocellular carcinoma [2].
机译：原发性肝癌是全球第五大最常见的癌症，也是第三大最常见的死于癌症的原因，每年导致超过600,000例死亡[1]。一方面，我们拥有可用于早期肝细胞癌的不同治疗机会（切除，射频或经皮乙醇注射局部消融，肝移植），另一方面，晚期肝癌仍面临挑战。有效治疗方案的匮乏。靶向疗法的引入代表了药物开发的新时代，并暗示了选择攻击对癌症存活和发展至关重要的途径的选择。特别是血管生成信号，通过酪氨酸激酶介导的生长信号通路似乎在肝细胞癌的发病机理中具有独特的作用[2]。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号